Alopecia - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 67 pages report, published by Global Markets Direct

Keywords : Alopecia Therapeutic Products under Development, Key Players in Alopecia Therapeutics, Alopecia Pipeline Overview, Alopecia Pipeline, Alopecia Pipeline Assessment

Report ThumbnailSeptember-2013
Alopecia - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Alopecia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Alopecia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alopecia. Alopecia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Alopecia.
- A review of the Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Alopecia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Alopecia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Alopecia, H2 2013 9
  • Products under Development for Alopecia - Comparative Analysis, H2 2013 10
  • Products under Development by Companies, H2 2013 11
  • Products under Investigation by Universities/Institutes, H2 2013 13
  • Mid Clinical Stage Products, H2 2013 14
  • Early Clinical Stage Products, H2 2013 15
  • Discovery and Pre-Clinical Stage Products, H2 2013 16
  • Assessment by Monotherapy Products, H2 2013 30
  • Assessment by Route of Administration, H2 2013 31
  • Assessment by Stage and Route of Administration, H2 2013 32
  • Assessment by Molecule Type, H2 2013 33
  • Assessment by Stage and Molecule Type, H2 2013 34
  • List of Tables
  • Number of Products Under Development for Alopecia, H2 2013 9
  • Products under Development for Alopecia - Comparative Analysis, H2 2013 10
  • Number of Products under Development by Companies, H2 2013 12
  • Number of Products under Investigation by Universities/Institutes, H2 2013 13
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 15
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 16
  • Products under Development by Companies, H2 2013 17
  • Products under Investigation by Universities/Institutes, H2 2013 18
  • Medicis Pharmaceutical Corporation, H2 2013 19
  • Taisho Pharmaceutical Co., Ltd., H2 2013 20
  • AntiCancer, Inc., H2 2013 21
  • HYUNDAI PHARM. CO., LTD., H2 2013 22
  • Panacea Biotec Limited, H2 2013 23
  • ProCertus BioPharm Inc., H2 2013 24
  • AndroScience Corporation, H2 2013 25
  • Hygeia Therapeutics, Inc., H2 2013 26
  • Kuhnil Pharmaceutical Co., Ltd., H2 2013 27
  • Ascenion GmbH, H2 2013 28
  • OmegaGenesis, Inc., H2 2013 29
  • Assessment by Monotherapy Products, H2 2013 30
  • Assessment by Stage and Route of Administration, H2 2013 32
  • Assessment by Stage and Molecule Type, H2 2013 34
  • Alopecia Therapeutics - Drug Profile Updates 56
  • Alopecia Therapeutics - Discontinued Products 58
  • Alopecia Therapeutics - Dormant Products 59
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Alopecia Overview 8
  • Therapeutics Development 9
  • An Overview of Pipeline Products for Alopecia 9
  • Alopecia Therapeutics under Development by Companies 11
  • Alopecia Therapeutics under Investigation by Universities/Institutes 13
  • Mid Clinical Stage Products 14
  • Comparative Analysis 14
  • Early Clinical Stage Products 15
  • Comparative Analysis 15
  • Discovery and Pre-Clinical Stage Products 16
  • Comparative Analysis 16
  • Alopecia Therapeutics - Products under Development by Companies 17
  • Alopecia Therapeutics - Products under Investigation by Universities/Institutes 18
  • Companies Involved in Alopecia Therapeutics Development 19
  • Medicis Pharmaceutical Corporation 19
  • Taisho Pharmaceutical Co., Ltd. 20
  • AntiCancer, Inc. 21
  • HYUNDAI PHARM. CO., LTD. 22
  • Panacea Biotec Limited 23
  • ProCertus BioPharm Inc. 24
  • AndroScience Corporation 25
  • Hygeia Therapeutics, Inc. 26
  • Kuhnil Pharmaceutical Co., Ltd. 27
  • Ascenion GmbH 28
  • OmegaGenesis, Inc. 29
  • Alopecia - Therapeutics Assessment 30
  • Assessment by Monotherapy Products 30
  • Assessment by Route of Administration 31
  • Assessment by Molecule Type 33
  • Drug Profiles 35
  • HYG-430 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • HYG-420 - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • HYG-410 - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • ASCJ-9 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • Lipo-4MA - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • CB-03-01 - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • Nanorods Topical - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • KI-1104 - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • KI-1105 - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • calcitriol - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • ALK5 Inhibitor - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • HOB-058 - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • P2Y5-Ligand LPA - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • Drug For Autoimmune Disorders - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • V-2248 - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • ProDermaCel - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • Transforming Growth Factor Beta Receptor Antagonists - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • PAI-1 Inhibitors - Drug Profile 55
  • Product Description 55
  • Mechanism of Action 55
  • R&D Progress 55
  • Alopecia Therapeutics - Drug Profile Updates 56
  • Alopecia Therapeutics - Discontinued Products 58
  • Alopecia Therapeutics - Dormant Products 59
  • Alopecia - Product Development Milestones 60
  • Featured News & Press Releases 60
  • Feb 04, 2013: RepliCel To Meet With German Competent Authority On Its RCH-01 Autologous Hair Cell Manufacturing Process 60
  • Nov 07, 2012: RepliCel Completes First Pre-Filing Review With German Competent Authority On RCH-01 Autologous Hair Cell Manufacturing Process 60
  • Oct 26, 2012: Glaucoma Drug Bimatoprost May Be Effective In Treating Alopecia, New Research In FASEB Journal Shows 61
  • Jul 23, 2012: Berg Pharma Launches Clinical Trial On BPM 31543 For Prevention Of Chemotherapy-induced Alopecia 61
  • Apr 11, 2012: FDA Announces Changes To Professional Labels For Propecia 62
  • Jan 24, 2011: R-Tech Ueno Completes Phase IIa Clinical Study Of RK-023 To Treat Androgenetic Alopecia 62
  • Oct 06, 2010: Cosmo Reports Positive Results In Alopecia Study With CB-03-01 63
  • Oct 06, 2009: R-Tech Ueno Initiates Early Phase II Clinical Trial For RK-023 64
  • Jul 16, 2009: Notification Of The Completion Of Phase I Clinical Study Of RK-023 64
  • May 30, 2006: Banyu Pharmaceutical Confirms Efficacy of Propecia in Long-term Administration. 65
  • Appendix 66
  • Methodology 66
  • Coverage 66
  • Secondary Research 66
  • Primary Research 66
  • Expert Panel Validation 66
  • Contact Us 67
  • Disclaimer 67

Please select a license type

Share

Related Products

Global Markets DirectAlopecia - Pipeline Review, H2 2013Product ThumbnailAlopecia - Pipeline Review, H2 2013, Industry ReportProduct #: 113293
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved